MICHAEL W. NALL
President & Chief Executive Officer, Biocept
Mr. Nall has over 25 years of healthcare sales and marketing experience, most recently serving at Clarient Diagnostic Services, Inc. in positions of increasing responsibility from 2002 through 2013. While at Clarient, Mr. Nall was also responsible for leading the team assimilating Clarient into GE Healthcare after being acquired in 2010. From 1988 until joining Clarient, Mr. Nall served in the diagnostic and medical device industries in various commercial leadership roles for companies including Impath, American Cyanamid, Maquet Surgical, Strato Medical, Horizon Medical Products and Columbia Vital Systems. Mr. Nall received a Bachelor of Science degree in Business Administration from Central Missouri State University (now known as the University of Central Missouri).
Completing the Answer in Oncology
Each patient deserves an answer about the molecular status of their tumor, but for some oncology patients, a surgical tissue biopsy is not possible or practical. By providing molecular status on both circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) at the both time of diagnosis and for monitoring, Biocept is helping physicians develop treatment plans for patients. Highly validated assays are focused on the biomarkers found in the NCCN guidelines, with a goal of improving outcomes, while reducing costs.